The symptoms of primaquine poisoning can vary but often include hemolytic anemia, which is the destruction of red blood cells. Patients may experience fatigue, jaundice (yellowing of the skin and eyes), dark urine, and shortness of breath. In severe cases, it can lead to acute kidney injury due to the breakdown of red blood cells. Other symptoms might include abdominal pain, nausea, and vomiting.

Diagnosing primaquine poisoning involves a thorough patient history and clinical examination. Key steps include:

• Blood Tests: To check for hemolytic anemia, including a complete blood count (CBC) and reticulocyte count.
• G6PD Testing: Since individuals with G6PD deficiency are at higher risk, testing for this enzyme deficiency is crucial.
• Liver and Kidney Function Tests: To assess any organ damage.
• Urinalysis: To detect hemoglobinuria, which indicates red blood cell breakdown.

The primary treatment for primaquine poisoning is to discontinue the drug immediately. Supportive care is essential and may include:

• Hydration: To help flush out the breakdown products of red blood cells.
• Blood Transfusions: In severe cases of anemia.
• Oxygen Therapy: If the patient is experiencing significant shortness of breath.
• Monitoring and Support: For kidney function and other vital signs.

The prognosis for primaquine poisoning largely depends on the severity of the reaction and the timeliness of treatment. Most patients recover fully with appropriate care, especially if the drug is discontinued promptly. However, severe cases can lead to complications such as kidney damage, which may require longer-term management.

Primaquine poisoning is primarily caused by the administration of primaquine in individuals who are sensitive to the drug. This sensitivity is often due to genetic factors, such as G6PD deficiency, which makes red blood cells more susceptible to oxidative damage.

Primaquine poisoning is relatively rare and is more common in populations with a high prevalence of G6PD deficiency. This genetic condition is more frequently found in individuals of African, Mediterranean, or Southeast Asian descent. The incidence of poisoning is also linked to the use of primaquine in malaria-endemic regions.

The pathophysiology of primaquine poisoning involves oxidative stress on red blood cells. In individuals with G6PD deficiency, the lack of this enzyme impairs the cell's ability to handle oxidative stress, leading to hemolysis. This results in the release of hemoglobin into the bloodstream, causing the symptoms associated with hemolytic anemia.

Preventing primaquine poisoning involves careful screening for G6PD deficiency before prescribing the medication. Genetic testing can identify at-risk individuals, allowing healthcare providers to choose alternative treatments for malaria. Educating patients about the potential risks and symptoms of poisoning is also crucial.

Primaquine poisoning is a serious but preventable condition that arises from the use of primaquine, particularly in individuals with G6PD deficiency. Early recognition and discontinuation of the drug are key to managing the condition effectively. With appropriate care, most patients recover without long-term consequences.

If you are prescribed primaquine, it is important to be aware of the potential for adverse reactions, especially if you have a family history of G6PD deficiency. Symptoms to watch for include fatigue, jaundice, and dark urine. If you experience any of these symptoms, contact your healthcare provider immediately. Testing for G6PD deficiency before starting primaquine can help prevent complications.